Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | CASP1 | P29466 | 1/20 | 0.40 |
| ▸ | HBB | P68871 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | CCR2 | P41597 | 9/20 | 0.40 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.35 |
| ▸ | PGR | P06401 | 1/20 | 0.35 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.35 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13995706 | 0.86 | TAAR1 (0.42) | KDM4EALDH1A1MEN1KMT2ANPC1 | |
| SCHEMBL15476680 | 0.81 | KDM4E (0.53) | KDM4EALDH1A1MEN1USP2GAA | |
| SCHEMBL13995843 | 0.79 | CHRM2 (0.53) | KDM4EALDH1A1MEN1GAAKMT2A | |
| SCHEMBL22513141 | 0.79 | CHRM2 (0.53) | KDM4EALDH1A1MEN1GAAKMT2A | |
| SCHEMBL13995728 | 0.79 | CHRM2 (0.53) | KDM4EALDH1A1MEN1GAAKMT2A | |
| SCHEMBL13995710 | 0.77 | RAPGEF4 (0.32) | — | |
| SCHEMBL12961020 | 0.76 | KDM4E (0.49) | KDM4EALDH1A1MEN1USP2GAA | |
| SCHEMBL172626 | 0.74 | CHRM2 (0.50) | KDM4EALDH1A1MEN1GAAMAPT | |
| SCHEMBL12652129 | 0.74 | KDM4E (0.47) | KDM4EALDH1A1MEN1USP2GAA | |
| SCHEMBL13195646 | 0.74 | ALDH1A1 (0.65) | KDM4EALDH1A1MEN1USP2GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7462625-B2 | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto | NEUROCRINE BIOSCIENCES, INC. (US) | 2008-12-09 | — | — | US | disclosed |
| US-20070208049-A1 | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto | NEUROCRINE BIOSCIENCES, INC. (US) | 2007-09-06 | — | — | US | disclosed |
| US-7179815-B2 | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto | NEUROCRINE BIOSCIENCES, INC. (US) | 2007-02-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070208049-A1 | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto | GNRHR, GHRHR, LHCGR | KDM4E 1846/4885ALDH1A1 3443/4885MEN1 510/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.